FinnCap restated their corporate rating on shares of Akers Biosciences Inc (LON:AKR) in a research note issued to investors on Tuesday.

Akers Biosciences (AKR) opened at GBX 56 ($0.74) on Tuesday. Akers Biosciences has a 1-year low of GBX 50 ($0.66) and a 1-year high of GBX 255 ($3.35).

COPYRIGHT VIOLATION NOTICE: “Akers Biosciences’ (AKR) “Corporate” Rating Reiterated at FinnCap” was published by Watch List News and is the property of of Watch List News. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at

About Akers Biosciences

Akers Biosciences, Inc develops, manufactures and supplies point-of-care screening and testing products designed to bring health-related information to the patient or clinician. The Company’s product offerings and pipeline products focus on delivering diagnostic assistance in a range of healthcare fields/specialties, including cardiology/emergency medicine, metabolism/nutrition, diabetes, respiratory diseases and infectious diseases detection, as well as for on and off-the-job alcohol safety initiatives.

Receive News & Ratings for Akers Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akers Biosciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.